COMBINATION_PRODUCT
BI 456906 - Formulation A
Formulation A
Status
Completed
Phase
Phase 1
Enrollment
30
Locations
1
Results
Not posted
Publications
0
Study summary
The main objective of this trial is to investigate relative bioavailability of BI 456906 formulation B and BI 456906 formulation C vs. BI 456906 formulation A.
Interventions
COMBINATION_PRODUCT
Formulation A
DRUG
Formulation B
DRUG
Formulation C
Timeline
First posted
Jan 13, 2025
Study start
Feb 10, 2025
Primary completion
May 29, 2025
Study completion
Jun 10, 2025
Results posted
Not reported
Registry updated
Mar 13, 2026
Outcomes
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz)
Time frame · Up to 22 days
Maximum measured concentration of the analyte in plasma (Cmax)
Time frame · Up to 22 days
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞)
Time frame · Up to 22 days
Eligibility
Inclusion Criteria: * Healthy male or female subjects according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (blood pressure (BP), pulse rate (PR)), 12-lead Electrocardiogram (ECG), and clinical laboratory tests. * Age of 18 to 55 years (inclusive). * Body mass index (BMI) of 20 to 29.9 kg/m² (inclusive) * Signed and dated written informed consent in accordance with International Council for Harmonisation-Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial. Further inclusion criteria apply. Exclusion Criteria: * Any finding in the medical examination (including BP, PR or ECG) deviating from normal and assessed as clinically relevant by the investigator. * Repeated measurement of systolic blood pressure outside the range of 90 to 140 millimetre(s) of mercury (mmHg), diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 45 to 90 beats per minute (bpm). * Any laboratory value outside the reference range that the investigator considers to be of clinical relevance. * Any evidence of a concomitant disease assessed as clinically relevant by the investigator. Further exclusion criteria apply.
Study locations
Germany. Showing up to 24 locations stored in the fast local snapshot.
Humanpharmakologisches Zentrum Biberach
Biberach/Riß, Germany
Publications
No PMID-linked publications were present in this registry snapshot.
Related trials
Boehringer Ingelheim · Healthy · Obesity
Phase 1
Recruiting
80
2026-07
Boehringer Ingelheim · Obesity
Phase 3
Completed
5,531
2026-07
Boehringer Ingelheim · Obesity
Phase 1
Active, not recruiting
29
2026-07
Boehringer Ingelheim · Metabolic Dysfunction Associated Steatohepatitis (MASH) · Liver Fibrosis
Phase 3
Recruiting
1,800
2026-07
Boehringer Ingelheim · Metabolic Dysfunction Associated Steatohepatitis
Phase 3
Recruiting
1,590
2026-07
Boehringer Ingelheim · Obesity · Diabetes Mellitus, Type 2
Phase 3
Completed
755
2026-06
Boehringer Ingelheim · Healthy · Obesity
Phase 1
Completed
56
2026-06
Boehringer Ingelheim · Obesity
Phase 1
Active, not recruiting
64
2026-05
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.